Loading
Hepatocellular Carcinoma Treatment and Prognosis · Journal article
Clinical Cancer Research · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical proof-of-concept study in orthotopic liver cancer xenografts showing that a GPC3-targeted alpha particle therapeutic (225Ac-GC33) paired with PET imaging (89Zr-GC33) achieves local tumor control and improved survival compared to unspecified control cohorts. The work demonstrates molecular targeting and imaging–therapy co-localization but lacks clinical evidence, comparative efficacy benchmarking, and formal statistical analysis.
Uncontrolled preclinical experimental study in orthotopic xenograft models. Orthotopic hepatocellular carcinoma xenograft models using HepG2 and Hep3B human cancer cells implanted in animals.. Intervention: [225Ac]Ac-Macropa-GC33 (GPC3-targeted alpha particle therapeutic); single 9.3 kBq dose. Compared with: Unspecified control cohorts.
Both 89Zr-GC33 and 225Ac-GC33 showed high tumor accumulation (>200 %IA/g) in HepG2 models with high overlap in biodistribution Single 9.3 kBq dose of 225Ac-GC33 produced excellent local control including several complete pathologic responses Improved overall survival in 225Ac-GC33-treated animals compared to control cohorts
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work demonstrates a mechanistic rationale for GPC3-targeted paired radiotheranostics in HCC but provides no direct evidence of clinical utility. Translation to human trials would be required to assess safety, dosimetry, imaging predictive value, and clinical benefit.
Preclinical proof-of-concept in orthotopic xenograft models demonstrating paired radiotheranostic imaging and therapy, without clinical translation, comparative efficacy data, or power calculations.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work demonstrates a mechanistic rationale for GPC3-targeted paired radiotheranostics in HCC but provides no direct evidence of clinical utility. Translation to human trials would be required to assess safety, dosimetry, imaging predictive value, and clinical benefit.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Purpose: Glypican-3 (GPC3), highly expressed in the most common liver cancer hepatocellular carcinoma (HCC) but absent from normal liver, represents an attractive tumor-selective target. We evaluated GPC3-targeted paired PET diagnostic and alpha particle therapeutic (radiotheranostic) agents in orthotopic models of liver cancer. Experimental Design: Using the GPC3-specific antibody codrituzumab (GC33), we engineered an immunoPET agent, [89Zr]Zr-DFO-GC33 (89Zr-GC33), and a therapeutic agent, [225Ac]Ac-Macropa-GC33 (225Ac-GC33). Binding specificity and biodistribution were assessed in orthotopic luciferase-expressing liver cancer models (HepG2 and Hep3B). Micro-scale co-localization of the pair was validated using quantitative particle identification (QPID) spectral autoradiography. Preclinical trial of therapeutic efficacy of a single 9.3 kBq administration of 225Ac-GC33 was conducted. Primary endpoints were local control, as assessed by longitudinal bioluminescence imaging (BLI) and immunoPET with 89Zr-GC33 with histological confirmation, and overall survival. Results: The biodistribution of 225Ac-GC33 closely mirrored that of 89Zr-GC33, with both agents showing high accumulation in HepG2 tumors (>200 percent injected activity per gram [%IA/g]) and high overlap in organ-level macrodistribution. Animals treated with 225Ac-GC33 showed excellent local control, including several complete pathologic responses, and improved overall survival compared to control cohorts. We also observed efficacy in orthotopic Hep3B tumors, suggesting activity even in tumors with moderate GPC3 expression. In both models, longitudinal 89Zr-GC33 immunoPET correlated with BLI. Conclusions: We show GPC3-specific PET imaging can predict and assess response to GPC3-targeted alpha particle therapy in orthotopic liver cancer models. This approach can address the unmet diagnostic and therapeutic needs for patients with liver cancer and may extend to other GPC3-expressing malignancies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.